AstraZeneca (AZN) Stock Price, Fundamentals & Analysis

What AZN does

AstraZeneca (AZN) is a biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines. Its portfolio includes treatments in oncology, cardiovascular, respiratory, and rare diseases, with products such as Imjudo, Tagrisso, Imfinzi, Lynparza, and Farxiga/Forxiga. The company is headquartered in Cambridge, United Kingdom, and trades on the London Stock Exchange as part of the FTSE 100.

Key numbers explained

• 125.52 GBP is the current share price, representing the cost to buy one share at this moment.
• The trailing P/E ratio of 25.1 shows how much investors pay per pound of recent earnings; a higher number can mean the market expects strong future growth.
• The forward P/E ratio of 14.7 uses expected future earnings, which can make the stock look cheaper if those estimates hold.
• 1.9% is the dividend yield, the annual dividend payment expressed as a percentage of the share price.
• The ex-dividend date of Aug 6, 2026 is the cutoff: you must own the stock before this date to receive the next dividend.
• 47% of earnings are paid out as dividends, indicating roughly half of profits are returned to shareholders.
• Beta of 0.21 suggests the stock tends to move less than the overall market, which can mean lower volatility.
• 194.67B GBP is the market capitalization, the total value of all outstanding shares.

What to watch

Stock prices are influenced by company-specific news, such as drug approvals or clinical trial results, as well as broader factors like interest rates and currency movements. For AZN, investors often track upcoming catalysts like the next earnings report on Oct 30, 2026. Comparing AZN with peers such as Haleon (HLN), GSK plc (GSK), or Smith & Nephew (SN) can provide context on sector trends. The stock is part of the London Stock Exchange stocks universe, where sector rotation and regulatory developments can affect valuations.